@article{719b543e8ef74148b59cecfd34da733a,
title = "Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer",
abstract = "A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.",
author = "K. Matsui and N. Masuda and M. Fukuoka and T. Yana and T. Hirashima and T. Komiya and M. Kobayashi and M. Kawahara and S. Atagi and M. Ogawara and S. Negoro and S. Kudoh and K. Furuse",
note = "Funding Information: This work was supported in part by a Grant-in-Aid for Cancer Research from the Japanese Ministry of Health and Welfare (7-23) and a grant from Bristol-Myers Squibb (Tokyo, Japan). We wish to thank Mr Seiji Ito, Oncology Department staff. Bristol-Myers Squibb, Tokyo, Japan, for his help in the data collection and analysis and Dr Luigi Lenaz, Medical Doctor, Bristol-Myers Squibb, Princeton, NJ, USA, for critically reviewing multiple drafts of the manuscript.",
year = "1998",
month = jun,
doi = "10.1038/bjc.1998.325",
language = "English (US)",
volume = "77",
pages = "1961--1965",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "11",
}